Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA psychiatry. 2015; 72(12):1235-1242. [PMC free article: PMC5037576] [PubMed: 26502112]

Ryan-Ibarra S, Induni M, Ewing D. Prevalence of medical marijuana use in California, 2012. Drug and alcohol review. 2015;34(2):141-146. [PubMed: 25255903]

Adler JN, Colbert JA. Clinical decisions. Medicinal use of marijuana--polling results. N Engl J Med. 2013;368(22):e30. [PubMed: 23718175]

114th Congress (2015-2016). H.R.2577 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017. https://www​.congress​.gov/bill/114th-congress​/house-bill/2577/summary/40 Accessed August 24, 2016.

Institute of Medicine (US). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Academies Press; 2011. [PubMed: 22553896]

Ward BW, Schiller JS, Goodman RA. Multiple chronic conditions among US adults: a 2012 update. Prev Chronic Dis 2014; 11:E62. [PMC free article: PMC3992293] [PubMed: 24742395]

Bonn-Miller M, Boden M, Bucossi M, Babson K. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014;40(1):23-30. [PubMed: 24205805]

Ilgen MA, Bohnert K, Kleinberg F, et al. Characteristics of adults seeking medical marijuana certification. Drug and alcohol dependence. 2013;132(3):654-659. [PubMed: 23683791]

Degenhardt L, Lintzeris N, Campbell G, et al. Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Drug and alcohol dependence. 2015;147(ebs, 7513587):144-150. [PubMed: 25533893]

Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain medicine (Malden, Mass). 2009;10(8):1434-1441. [PubMed: 19793342]

Bowles DW. Persons registered for medical marijuana in the United States. J Palliat Med. 2012;15(1):9-11. [PubMed: 22268404]

Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2013;22(3):277-284. [PubMed: 23617872]

Kansagara D, O'Neil ME, Morasco B, et al. Cannabis for the management of symptoms of chronic pain and/or PTSD. PROSPERO International prospective register of systematic reviews. http://www​.crd.york.ac​.uk/prospero/display_record​.asp?ID=CRD42016033623 Accessed August 24, 2016.

Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473. [PubMed: 26103030]

Butler M, Krebs E, Sunderlin B, Kane R. Medical Cannabis for Non-Cancer Pain: A Systematic Review. 2015; http://www​.health.state​.mn.us/topics/cannabis​/intractable/medicalcannabisreport​.pdf. Accessed April 26, 2016.

Wilkinson ST, Radhakrishnan R, D'Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. J Clin Psychiatry. 2016;77(8):1050-1064. [PubMed: 27561138]

Oregon Health Authority. Medical Marijuana Rules and Statutes. Medical Marijuana Program (OMMP). https://public​.health​.oregon.gov/DiseasesConditions​/ChronicDisease​/MedicalMarijuanaProgram​/Pages/legal.aspx. Accessed October 3, 2016.

Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC medical research methodology. 2007;7:10. [PMC free article: PMC1810543] [PubMed: 17302989]

Wallace BC, Small K, Brodley CE, Lau J, Trikalinos TA. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr. Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium (IHI). 2012:819-824.

Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chapter 8: Assessing risk of bias in included studies. The Cochrane Collaboration, 2011. Accessed at www​.handbook.cochrane.org on January 16, 2017. 2011.

Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www​.ohri.ca/programs​/clinical_epidemiology/oxford.asp. Accessed January 11, 2016.

Viswanathan M, Ansari M, Berkman N, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Rockville, MD: Agency for Healthcare Research and Quality; Methods Guide for Comparative Effectiveness Reviews (AHRQ Publication No. 12-EHC047-EF); 2012. [PubMed: 22764383]

Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random effects. Stat Med. 1996;15(6):619-629. [PubMed: 8731004]

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557-560. [PMC free article: PMC192859] [PubMed: 12958120]

Berkman N, Lohr K, Ansari M, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Rockville, MD: Agency for Healthcare Research and Quality; Methods Guide for Comparative Effectiveness Reviews (AHRQ Publication No. 13(14)-EHC130-EF); 2013.

Atkins D, Chang S, Gartlehner G, et al. Assessing the Applicability of Studies When Comparing Medical Interventions. Rockville, MD: Agency for Healthcare Research and Quality; Methods Guide for Comparative Effectiveness Reviews (AHRQ Publication No. 11-EHC019-EF); 2011.

Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex() ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology. 2011;18(9):1122-1131. [PubMed: 21362108]

Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Advances in alcohol & substance abuse. 1987;7(1):39-50. [PubMed: 2831701]

Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Multiple sclerosis (Houndmills, Basingstoke, England). 2012;18(2):219-228. [PubMed: 21878454]

Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical rehabilitation. 2003;17(1):21-29. [PubMed: 12617376]

Ware MA, Wang T, Shapiro S, Collet J-P, team Cs. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). The journal of pain : official journal of the American Pain Society. 2015;16(12):1233-1242. [PubMed: 26385201]

Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflammatory bowel diseases. 2014;20(3):472-480. [PubMed: 24407485]

Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia. 2004;59(5):440-452. [PubMed: 15096238]

Fiz J, Duran M, Capella D, Carbonell J, Farre M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PloS one. 2011;6(4):e18440. [PMC free article: PMC3080871] [PubMed: 21533029]

Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515-521. [PubMed: 17296917]

Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112(3):299-306. [PubMed: 15561385]

Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009;34(3):672-680. [PMC free article: PMC3066045] [PubMed: 18688212]

Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal of pain and symptom management. 2014;47(1):166-173. [PubMed: 23742737]

Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1-3):210-220. [PubMed: 17997224]

Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes care. 2010;33(1):128-130. [PMC free article: PMC2797957] [PubMed: 19808912]

Serpell M, Ratcliffe S, Hovorka J, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European journal of pain (London, England). 2014;18(7):999-1012. [PubMed: 24420962]

Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. The journal of pain : official journal of the American Pain Society. 2015;16(7):616-627. [PMC free article: PMC5152762] [PubMed: 25843054]

Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2010;182(14):E694-701. [PMC free article: PMC2950205] [PubMed: 20805210]

Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. The journal of pain : official journal of the American Pain Society. 2008;9(6):506-521. [PMC free article: PMC4968043] [PubMed: 18403272]

Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. The journal of pain : official journal of the American Pain Society. 2013;14(2):136-148. [PMC free article: PMC3566631] [PubMed: 23237736]

Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, Phan A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. The Journal of Pain. 2016;17(9):982-1000. [PMC free article: PMC5007175] [PubMed: 27286745]

Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451-459. [PubMed: 20307378]

Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2012;184(10):1143-1150. [PMC free article: PMC3394820] [PubMed: 22586334]

Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. Journal of neurology. 2013;260(4):984-997. [PubMed: 23180178]

Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819. [PubMed: 16186518]

van Amerongen G, Kanhai K, Baakman AC, et al. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of δ9-Tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. Clinical Therapeutics. 2017. [PubMed: 28189366]

Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple sclerosis (Houndmills, Basingstoke, England). 2004;10(4):434-441. [PubMed: 15327042]

Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (London, England). 2003;362(9395):1517-1526. [PubMed: 14615106]

Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, Group MR. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. Journal of neurology, neurosurgery, and psychiatry. 2012;83(11): 1125-1132. [PubMed: 22791906]

Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of pain and symptom management. 2010;39(2): 167-179. [PubMed: 19896326]

Noyes R, Jr., Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical pharmacology and therapeutics. 1975;18(1):84-89. [PMC free article: PMC8332526] [PubMed: 50159]

Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. The journal of pain : official journal of the American Pain Society. 2012;13(5):438-449. [PubMed: 22483680]

De Vries M, Van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, Van Goor H. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. Clinical gastroenterology and hepatology. 2016;(no pagination). [PubMed: 27720917]

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford, England). 2006;45(1):50-52. [PubMed: 16282192]

Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. The Journal of clinical psychiatry. 2015;76(9):1174-1180. [PMC free article: PMC6258013] [PubMed: 26455669]

Johnson MJ, Pierce JD, Mavandadi S, et al. Mental health symptom severity in cannabis using and non-using Veterans with probable PTSD. J Affect Disord 2016;190:439-442. [PubMed: 26551402]

Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. Journal of clinical psychopharmacology. 2014;34(5):559-564. [PMC free article: PMC4165471] [PubMed: 24987795]

Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS neuroscience & therapeutics. 2009;15(1):84-88. [PMC free article: PMC6494011] [PubMed: 19228182]

Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51(7612148, qgc):585-588. [PubMed: 25467221]

Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev AY. Preliminary, open-label, pilot study of add-on oral Δ[superscript]9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clinical Drug Investigation. 2014;34(8):587-591. [PubMed: 24935052]

Mashiah M. Medical Cannabis as treatment for chronic combat PTSD: promising results in an open pilot tudy. Patients Out of Time Conference. Tucson, AZ. 2012.

Reznik I. Medical marijuana/cannabis use in patients with post-traumatic stress disorder. The International Conference on Integrative Medicine. Jerusalem, Israel. 2011.

Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Archives of internal medicine. 2007;167(3):221-228. [PMC free article: PMC2720277] [PubMed: 17296876]

Hancox RJ, Poulton R, Ely M, et al. Effects of cannabis on lung function: a population-based cohort study. The European respiratory journal. 2010;35(1):42-47. [PMC free article: PMC3805041] [PubMed: 19679602]

Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012;307(2):173-181. [PMC free article: PMC3840897] [PubMed: 22235088]

Tashkin DP, Simmons MS, Sherrill DL, Coulson AH. Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age. American journal of respiratory and critical care medicine. 1997;155(1): 141-148. [PubMed: 9001303]

Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman MA. Marijuana use and long-term mortality among survivors of acute myocardial infarction. American heart journal. 2013;165(2): 170-175. [PMC free article: PMC3558923] [PubMed: 23351819]

Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805-2809. [PubMed: 11401936]

Carvalho MFFd, Dourado MR, Fernandes IB, Araujo CTP, Mesquita AT, Ramos-Jorge ML. Head and neck cancer among marijuana users: a meta-analysis of matched case-control studies. Archives of Oral Biology. 2015;60(12): 1750-1755. [PubMed: 26433192]

Zhang LR, Morgenstern H, Greenland S, et al. Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. International journal of cancer Journal international du cancer. 2015;136(4):894-903. [PMC free article: PMC4262725] [PubMed: 24947688]

Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer causes & control : CCC. 2013;24(10): 1811-1820. [PubMed: 23846283]

Gurney J, Shaw C, Stanley J, Signal V, Sarfati D. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer 2015;15:897. [PMC free article: PMC4642772] [PubMed: 26560314]

Chacko JA, Heiner JG, Siu W, Macy M, Terris MK. Association between marijuana use and transitional cell carcinoma. Urology. 2006;67(1):100-104. [PubMed: 16413342]

Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016. [PubMed: 26878835]

Ronen A, Gershon P, Drobiner H, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accident; analysis and prevention. 2008;40(3):926-934. [PubMed: 18460360]

Lenne MG, Dietze PM, Triggs TJ, Walmsley S, Murphy B, Redman JR. The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand. Accident; analysis and prevention. 2010;42(3):859-866. [PubMed: 20380913]

Grotenhermen F, Leson G, Berghaus G, et al. Developing limits for driving under cannabis. Addiction (Abingdon, England). 2007;102(12):1910-1917. [PubMed: 17916224]

Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. Journal of Affective Disorders. 2016;195:63-74. [PubMed: 26872332]

Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (London, England). 2007;370(9584):319-328. [PubMed: 17662880]

Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: A systematic review and meta-analysis. European Psychiatry. 2015;30((Gibbs M.; Winsper C.; Marwaha S.; Gilbert E.; Singh S.P.) Warwick Medical School, University of Warwick, Coventry, United Kingdom):1128.

Kuepper R, van Os J, Lieb R, Wittchen H-U, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ (Clinical research ed). 2011;342:d738. [PMC free article: PMC3047001] [PubMed: 21363868]

Dominguez M, Saka MC, Lieb R, Wittchen HU, van Os J. Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study. The American journal of psychiatry. 2010;167(9):1075-1082. [PubMed: 20634371]

Rossler W, Hengartner MP, Angst J, Ajdacic-Gross V. Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years. Addiction (Abingdon, England). 2012;107(6):1174-1184. [PubMed: 22151745]

Kaufmann RM, Kraft B, Frey R, et al. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry. 2010;43(1):24-32. [PubMed: 20178093]

Mason OJ, Morgan CJM, Stefanovic A, Curran HV. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophrenia research. 2008;103(1-3):138-142. [PubMed: 18387788]

Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of psychopharmacology (Oxford, England). 2013;27(1):19-27. [PubMed: 23042808]

Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. The British journal of psychiatry : the journal of mental science. 2009;195(6):488-491. [PMC free article: PMC2801827] [PubMed: 19949195]

Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Experimental and clinical psychopharmacology. 2012;20(5):420-429. [PubMed: 22731735]

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders--Fifth Edition (DSM-5). Washington, DC2013.

World Health Organization. International Classification of Diseases--Tenth Revision (ICD-10). Geneva, Switzerland1999.

Bonn-Miller MO, Harris AHS, Trafton JA. Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychological services. 2012;9(4):404-416. [PubMed: 22564034]

Blanco C, Hasin DS, Wall MM, et al. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. JAMA psychiatry. 2016;73(4):388-395. [PubMed: 26886046]

Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. The journal of pain : official journal of the American Pain Society. 2007;8(7):573-582. [PMC free article: PMC1959336] [PubMed: 17499555]

Hefner K, Sofuoglu M, Rosenheck R. Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain. The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 2015;24(6):538-545. [PubMed: 26246069]

Bonn-Miller MO, Moos RH, Boden MT, Long WR, Kimerling R, Trafton JA. The impact of posttraumatic stress disorder on cannabis quit success. The American journal of drug and alcohol abuse. 2015;41(4):339-344. [PubMed: 26043369]

Walsh K, Elliott JC, Shmulewitz D, et al. Trauma exposure, posttraumatic stress disorder and risk for alcohol, nicotine, and marijuana dependence in Israel. Comprehensive psychiatry. 2014;55(3):621-630. [PMC free article: PMC3965593] [PubMed: 24387979]

Kevorkian S, Bonn-Miller MO, Belendiuk K, Carney DM, Roberson-Nay R, Berenz EC. Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors. 2015;29(3):633-638. [PMC free article: PMC4699174] [PubMed: 26415060]

Bonn-Miller MO, Boden MT, Vujanovic AA, Drescher KD. Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder symptoms among veterans in residential treatment. Psychological Trauma: Theory, Research, Practice, and Policy. 2013;5(2):193-200.

Cescon DW, Page AV, Richardson S, Moore MJ, Boerner S, Gold WL. Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol. 2008;26(13):2214-2215. [PubMed: 18445848]

Chusid MJ, Gelfand JA, Nutter C, Fauci AS. Letter: Pulmonary aspergillosis, inhalation of contaminated marijuana smoke, chronic granulomatous disease. Ann Intern Med. 1975;82(5):682-683. [PubMed: 1094876]

Marks WH, Florence L, Lieberman J, et al. Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient. Transplantation. 1996;61(12):1771-1774. [PubMed: 8685958]

Kagen SL, Kurup VP, Sohnle PG, Fink JN. Marijuana smoking and fungal sensitization. The Journal of allergy and clinical immunology. 1983;71(4):389-393. [PubMed: 6833678]

Munckhof WJ, Konstantinos A, Wamsley M, Mortlock M, Gilpin C. A cluster of tuberculosis associated with use of a marijuana water pipe. Int J Tuberc Lung Dis. 2003;7(9):860-865. [PubMed: 12971670]

Oeltmann JE, Oren E, Haddad MB, et al. Tuberculosis outbreak in marijuana users, Seattle, Washington, 2004. Emerging infectious diseases. 2006;12(7):1156-1159. [PMC free article: PMC3291049] [PubMed: 16836841]

Ramos S, Rodrigues R, Almeida N, Sá JM, Fonseca L. Cannabinoid hyperemesis syndrome. Psychotherapy and Psychosomatics. 2013;82((Ramos S.; Rodrigues R.; Almeida N.; Fonseca L.) Department of Psychiatry, Centro Hospitalar Alto Ave, Guimarães, Portugal):90.

Sadiq M. Cannabis hyperemesis syndrome. Journal of Addiction Medicine. 2013; 7(4):E3.

Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Digestive diseases and sciences. 2010;55(11):3113-3119. [PubMed: 20130993]

Velasco A, Pentecost P. An unexpected etiology of cyclical vomiting. Journal of Hospital Medicine. 2012;7((Velasco A.; Pentecost P.) University of New Mexico, School of Medicine, Albuquerque, United States):S281.

Vujasinović M, Ivartnik M, Tretjak M. Cannabinoid hyperemesis syndrome - Case report. Zdravniski Vestnik. 2012;81(2):159-162.

Welder JD. Some like it hot: A case of cannabinoid hyperemesis syndrome. Journal of General Internal Medicine. 2012;27((Welder J.D.) University of Iowa, Iowa City, United States):S480-S481.

Woods JA, Wright NJ, Gee J, Scobey MW. Cannabinoid Hyperemesis Syndrome: An Emerging Drug-Induced Disease. Am J Ther. 2016;23(2):e601-605. [PubMed: 24413371]

Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clinic proceedings. 2012;87(2):114-119. [PMC free article: PMC3538402] [PubMed: 22305024]

Brandenburg D, Wernick R. Intravenous marijuana syndrome. West J Med. 1986;145(1):94-96. [PMC free article: PMC1306836] [PubMed: 3489321]

Carabellese F, Candelli C, Martinelli D, La Tegola D, Catanesi R. Cannabis use and violent behaviour: a psychiatric patients cohort study in Southern Italy. Rivista di psichiatria. 2013;48(1):43-50. [PubMed: 23438700]

Myerscough R, Taylor S. The effects of marijuana on human physical aggression. Journal of personality and social psychology. 1985;49(6):1541-1546. [PubMed: 3003332]

Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addictive behaviors. 2014;39(10):1430-1433. [PubMed: 24930049]

Lamy FR, Daniulaityte R, Sheth A, et al “Those edibles hit hard”: Exploration of Twitter data on cannabis edibles in the U.S. Drug Alcohol Depend. 2016;164:64-70. [PMC free article: PMC4893972] [PubMed: 27185160]

Hudak M, Severn D, Nordstrom K. Edible Cannabis-Induced Psychosis: Intoxication and Beyond. Am J Psychiatry. 2015;172(9):911-912. [PubMed: 26324307]

Meier MH, Caspi A, Cerda M, et al. Associations Between Cannabis Use and Physical Health Problems in Early Midlife: A Longitudinal Comparison of Persistent Cannabis vs Tobacco Users. JAMA Psychiatry. 2016;73(7):731-740. [PMC free article: PMC4936934] [PubMed: 27249330]

Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products. Jama. 2015;313(24):2491-2493. [PubMed: 26103034]

Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: a systematic review. Archives of internal medicine. 2006;166(13):1359-1367. [PubMed: 16832000]

Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry. 2012;2:e94. [PMC free article: PMC3316151] [PubMed: 22832859]

Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24(1):51-64. [PubMed: 24309088]

Management of Post-Traumatic Stress Working Group. VA/DoD Clinical Practice Guidelines for Management of Post-Traumatic Stress, Version 2.0. Department of Veteran Affairs and Department of Defense. 2010; http://www​.healthquality​.va.gov/guidelines​/MH/ptsd/cpg_PTSD-FULL-201011612.pdf. Accessed November 4, 2016.

Treatment for Posttraumatic Stress Disorder in Military and Veteran Populations, Final Assessment. Washington, DC: Institute of Medicine; http://iom​.nationalacademies​.org/Reports​/2014/Treatment-for-Posttraumatic-Stress-Disorder-in-Military-and-Veteran-Populations-Final-Assessment.aspx, Accessed November 4, 2016. 2014. [PubMed: 25077185]

Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports. 2016;65(1):1-49. [PubMed: 26987082]

Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clinical pharmacology and therapeutics. 2011;90(6):844-851. [PubMed: 22048225]

DeGeorge M, Dawson E, Woster P, Ko M, Burke L, Bronstein K. An analysis of the association between marijuana use and potential nonadherence in patients prescribed hydrocodone. Poster session presented at the 2013 annual meeting of the American Academy of Pain Medicine. Fort Lauderdale, FL: 2013, April. Retrieved from http://www​.painmed.org​/2013posters/poster114.pdf. Accessed August 25, 2016.

Ashrafioun L, Bohnert KM, Jannausch M, Ilgen MA. Characteristics of substance use disorder treatment patients using medical cannabis for pain. Addictive behaviors. 2015;42(2gw, 7603486):185-188. [PubMed: 25481452]

Haroutounian S, Ratz Y, Ginosar Y, et al. The Effect of Medicinal Cannabis on Pain and Quality of Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. 2016. [PubMed: 26889611]

Saint Louis C, Apuzzoaug M. Obama Administration Set to Remove Barrier to Marijuana Research. The New York Times. August 10, 2016. http://www​.nytimes.com​/2016/08/11/science​/obama-administration-set-to-remove-barrier-to-marijuana-research​.html?emc=eta1&_r=0 Accessed August 25, 2016.

van Nierop M, Janssens M, Genetic Risk OoPI, et al. Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PloS one. 2013;8(11):e76690. [PMC free article: PMC3819353] [PubMed: 24223116]